Skip to main content

Table 3 The bivariate logistic regression for comparing demographic and clinical information of cancer patients

From: The prevalence and predictors of herb-drug interactions among Iranian cancer patients during chemotherapy courses

Variable

Level of variable

cORa

(95% CIb)

P-value

Agec

0.99

(0.97–1.01)

0.80

Sex

Male

1

–

Female

2.28

(1.22–4.26)

0.01

Marital status

Single

1

–

Married

1.05

(0.28–3.91)

0.93

Area of residence

Urban

1

–

Rural

0.87

(0.42–1.76)

0.70

Education level

Under diploma

1

–

Diploma and more

1.58

(0.84–2.97)

0.15

Cancer site

Breast

1

–

Gastrointestinal

0.09

(0.03–0.24)

 ≤ 0.0001

Lymphoma and hematologic tumors

0.31

(0.10–0.91)

0.03

Gynecologic

0.69

(0.07–6.27)

0.74

Thorax

0.33

(0.10–1.07)

0.06

Other sites

0.20

(0.04–0.95)

0.04

Clinical stage

I

1

–

II

2.5

(0.70–8.92)

0.15

III

2.16

(0.64–7.33)

0.21

IV

4.12

(0.98–17.19)

0.05

Unclear

1.58

(0.54–4.62)

0.39

Metastatic status

Negative

1

–

Positive

1.25

(0.67–2.34)

0.46

Unclear

0.27

(0.05–1.43)

0.12

Recurrence status

Negative

1

–

Positive

1.39

(0.58–3.34)

0.45

Unclear

0.19

(0.04–0.89)

0.03

Comorbid illness

Negative

1

–

Positive

1.37

(0.75–2.51)

0.29

Nausea and vomiting

Negative

1

–

Positive

1.77

(0.94–3.31)

0.07

Constipation and diarrhea

Negative

1

–

Positive

1.08

(0.58–2.02)

0.79

Pain

Negative

1

–

Positive

3.16

(1.70–5.87)

 ≤ 0.0001

Oral lesions

Negative

1

–

Positive

1.66

(0.90–3.06)

0.10

Skin lesions

Negative

1

–

Positive

1.35

(0.73–2.46)

0.32

Number of chemotherapeutic agentsc

1.75

(1.40–2.19)

 ≤ 0.0001

Number of herbal medicinesc

1.12

(1.05–1.20)

 ≤ 0.0001

  1. aCrude Odds Ratio
  2. bConfidence Intervals
  3. cThese variables were considered as continuous in the analysis